These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 26402007)
1. Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. Lewczuk P; Kornhuber J; ; Toledo JB; Trojanowski JQ; Knapik-Czajka M; Peters O; Wiltfang J; Shaw LM; J Alzheimers Dis; 2015; 48(2):433-41. PubMed ID: 26402007 [TBL] [Abstract][Full Text] [Related]
2. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
3. The Erlangen Score Algorithm in the diagnosis and prediction of the progression from subjective cognitive decline and mild cognitive impairment to Alzheimer-type dementia. Filipek-Gliszczyńska A; Barczak A; Budziszewska M; Mandecka M; Gabryelewicz T; Barcikowska M Folia Neuropathol; 2018; 56(2):88-96. PubMed ID: 30509028 [TBL] [Abstract][Full Text] [Related]
4. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311 [TBL] [Abstract][Full Text] [Related]
7. A data-driven model of biomarker changes in sporadic Alzheimer's disease. Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC; Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224 [TBL] [Abstract][Full Text] [Related]
8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
9. Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Somers C; Lewczuk P; Sieben A; Van Broeckhoven C; De Deyn PP; Kornhuber J; Martin JJ; Bjerke M; Engelborghs S J Alzheimers Dis; 2019; 68(3):1151-1159. PubMed ID: 30883344 [TBL] [Abstract][Full Text] [Related]
10. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM; JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480 [TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
13. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
14. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043 [TBL] [Abstract][Full Text] [Related]
15. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
18. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824 [TBL] [Abstract][Full Text] [Related]
19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Ben Bouallègue F; Mariano-Goulart D; Payoux P; Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967 [TBL] [Abstract][Full Text] [Related]
20. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]